The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS

NCT03151005 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of GLP-1 agonists and oral contraceptives (OCs) on reproductive function and cardiovascular risks in women who are overweight and have polycystic ovary syndrome (PCOS).

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 70 people

Who can join Ages 18–50 · female only

Timeline Started 2017-07 · est. completion 2021-04

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT03151005 ↗

Description as written by the study sponsor.

Polycystic ovary syndrome (PCOS) is a health problem that affects one in 10 women of childbearing age, which is usually characterized by hormonal imbalance and metabolism problems such as hyperandrogenism and obesity. Diane 35 pills are classified as oral contraceptives, which effectively reduces circulating androgens and are treatment for hyperandrogenism caused androgenic skin symptoms and irregular menstrual cycles. GLP-1 Receptor Agonist(e.g. exenatide, liraglutide) have the effects of lowering blood sugar and weight control by inhibiting of gastric emptying and reducing food intake. This study aims to evaluate the effect of metformin-GLP-1 Receptor agonist combination versus metformin-Diane-35 combination treatment on lipid metabolism and cardiovascular risks in overweight polycystic ovarian syndrome (PCOS) patients.

Treatments tested

Metformin-GLP-1 Receptor Agonist also known as Metformin-exenatide/liraglutide Therapy Drug

metformin oral with exenatide/liraglutide subcutaneous injection.
Metformin-Oral Contraceptive(OC) also known as Metformin, Diane 35 Drug

metformin with Diane 35 oral intake.

Main thing measured	Assessment of Reproductive Functions
Sponsor	Xinqiao Hospital of Chongqing
Conditions studied	Polycystic Ovary Syndrome (PCOS), Overweight, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03151005 ↗